OmniAb, Inc. (NASDAQ:OABI) announced an insider transaction on April 7, 2026 in which Director Matthew W. Foehr, who also serves as President and CEO, sold 19,244 shares of the company's common stock for roughly $28,673. The shares changed hands at a weighted average price of $1.49, with individual sale prices in the range of $1.46 to $1.53.
Alongside the sale, Foehr acquired 36,459 shares of common stock and had 36,459 Restricted Stock Units converted into common stock. Those acquisitions were recorded with a price of $0.
After completing these transactions, Foehr's direct holdings in OmniAb consist of 4,420,492 shares of common stock and 309,376 Restricted Stock Units.
InvestingPro data shows OmniAb is trading at $1.51, representing an 18% decline year-to-date. InvestingPro analysis also indicates the stock is currently trading above its Fair Value, although professional analysts continue to express a favorable stance on the company's prospects.
For subscribers, InvestingPro offers additional resources for OABI, including six extra ProTips and an in-depth Pro Research Report that are available exclusively to OABI subscribers.
OmniAb's fourth-quarter fiscal 2025 financials were released alongside the insider activity. The company reported revenue of $8.4 million for the quarter, down from $10.8 million in the same period the prior year. OmniAb posted a net loss of $14.2 million, or $0.11 per share, compared with a net loss of $0.12 per share in the fourth quarter of fiscal 2024.
Despite those results, a number of analyst firms maintained positive ratings for the company. Benchmark kept a Buy rating with a $4.00 price target. Stifel reaffirmed a Buy rating and a $9.00 price target, citing year-over-year increases in engagement metrics - specifically a 17% rise in active partners and a 12% increase in programs - which Stifel described as supportive of the research and development environment.
Truist Securities also reiterated a Buy rating, noting constructive management discussions and a biotech sector recovery as favorable factors. Leerink Partners maintained an Outperform rating with a $10.00 price target and stated that the failure of a partner's trial did not alter its view of OmniAb's outlook.
The combination of insider selling, equity conversions, a revenue decline, and continued analyst support frames the current market narrative for OmniAb. Investors seeking further analysis can consult the paid InvestingPro tools referenced by the platform for expanded commentary and research on OABI.
Note: The figures and analyst positions cited above are taken from the company's filings and InvestingPro data as reported.